BiotechTube

3-drug anti-HIV therapy + Raltegravir

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Human Immunodeficiency Virus

Conditions

Human Immunodeficiency Virus

Trial Timeline

Feb 1, 2009 → Oct 1, 2013

NCT ID
NCT00781287

About 3-drug anti-HIV therapy + Raltegravir

3-drug anti-HIV therapy + Raltegravir is a approved stage product being developed by Merck for Human Immunodeficiency Virus. The current trial status is terminated. This product is registered under clinical trial identifier NCT00781287. Target conditions include Human Immunodeficiency Virus.

What happened to similar drugs?

13 of 20 similar drugs in Human Immunodeficiency Virus were approved

Approved (13) Terminated (3) Active (7)
✅lopinavir/ritonavirAbbVieApproved
✅emtricitabine/tenofovir disoproxil fumarateMerckApproved
✅Human Papillomavirus 9-valent Vaccine, RecombinantMerckApproved
✅GardasilMerckApproved
✅RaltegravirMerckApproved
✅RaltegravirMerckApproved
✅EBR/GZRMerckApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00781287ApprovedTerminated

Competing Products

20 competing products in Human Immunodeficiency Virus

See all competitors
ProductCompanyStageHype Score
Influenza vaccine, split inactivatedComac MedicalPhase 1
19
CS-8958 + CS-8958 + oseltamivir phosphateDaiichi SankyoPhase 3
40
GSK1265744 30mg + Placebo + GSK1265744 5mgShionogiPhase 2
35
DolutegravirShionogiPhase 3
40
GSK1349572 + efavirenzShionogiPhase 2
35
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
29
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
29
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg + Dolutegravir 50 mg + abacavir 600 mg/lamivudine 300 mgShionogiPhase 1
29
GSK1349572 (dolutegravir) + raltegravirShionogiPhase 3
40
Ortho-Cyclen + Dolutegravir + PlaceboShionogiPhase 1
29
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusionShionogiPhase 1
29
dolutegravirShionogiPhase 3
40
Dolutegravir + Atripla + Abacavir/Lamivudine + Abacavir/Lamivudine Placebo + Dolutegravir placebo + Atripla placeboShionogiPhase 3
40
GSK1349572 + EfavirenzShionogiPhase 1
29
GSK1349572ShionogiPhase 1
29
GSK1349572 + PlaceboShionogiPhase 2
35
Dolutegravir + MethadoneShionogiPhase 1
29
GSK1349572 + Raltegravir + GSK1349572 Placebo + Raltegravir PlaceboShionogiPhase 3
40
GSK1349572 + Rifampin + RifabutinShionogiPhase 1
29
DTG + BCV + TVRShionogiPhase 1
29